Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions: 24-Month Results of IN.PACT SFA.
暂无分享,去创建一个
Hong Wang | D. Scheinert | M. Jaff | P. Krishnan | D. Cohen | M. Brodmann | G. Tepe | J. Laird | Melissa S. Hasenbank | T. Zeller | P. Schneider | A. Micari | C. Metzger | D. Cohen
[1] D. Scheinert,et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. , 2015, The New England journal of medicine.
[2] G. Tepe,et al. Drug-Coated Balloon versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and/or Popliteal Peripheral Artery Disease: 12-Month Results From the IN.PACT SFA Randomized Trial , 2015 .
[3] S. Duda,et al. Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: Outcomes from the ILLUMENATE first‐in‐human study , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[4] Jae Joong Lee,et al. Comparison of diabetic and non-diabetic patients undergoing endovascular revascularization for peripheral arterial disease. , 2015, The Journal of invasive cardiology.
[5] J. Matsumura,et al. A single stent strategy in patients with lifestyle limiting claudication: 3‐year results from the Durability II trial , 2015, Catheterization and Cardiovascular Interventions.
[6] D. Scheinert,et al. Drug-Coated Balloon Versus Standard Percutaneous Transluminal Angioplasty for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease , 2015, Circulation.
[7] T. Mueller,et al. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. , 2014, Journal of vascular surgery.
[8] D. Scheinert,et al. Nitinol Stent Implantation in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the Complete SE Multicenter Trial , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[9] D. Dawson,et al. Nitinol Self-Expanding Stents vs. Balloon Angioplasty for Very Long Femoropopliteal Lesions , 2014, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[10] M. Dake,et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. , 2013, Journal of the American College of Cardiology.
[11] T. Albrecht,et al. Paclitaxel-Coated Balloons Reduce Restenosis After Femoro-Popliteal Angioplasty: Evidence From the Randomized PACIFIER Trial , 2012, Circulation. Cardiovascular interventions.
[12] M. Böhm,et al. Do Pharmacokinetics Explain Persistent Restenosis Inhibition by a Single Dose of Paclitaxel? , 2012, Circulation. Cardiovascular interventions.
[13] M. Buchbinder,et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[14] M. Nobuyoshi,et al. Classification and clinical impact of restenosis after femoropopliteal stenting. , 2012, Journal of the American College of Cardiology.
[15] J. Laird,et al. The treatment of femoropopliteal in-stent restenosis: back to the future. , 2012, Journal of the American College of Cardiology.
[16] M. Dake,et al. Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease: Twelve-Month Zilver PTX Randomized Study Results , 2011, Circulation. Cardiovascular interventions.
[17] Maurice Buchbinder,et al. Nitinol Stent Implantation Versus Balloon Angioplasty for Lesions in the Superficial Femoral Artery and Proximal Popliteal Artery: Twelve-Month Results From the RESILIENT Randomized Trial , 2010, Circulation. Cardiovascular interventions.
[18] Johannes Lammer,et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[19] A. Dyer,et al. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. , 2008, Journal of vascular surgery.
[20] B. Hamm,et al. Inhibition of Restenosis in Femoropopliteal Arteries: Paclitaxel-Coated Versus Uncoated Balloon: Femoral Paclitaxel Randomized Pilot Trial , 2008, Circulation.
[21] C. Claussen,et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. , 2008, The New England journal of medicine.
[22] L. Norgren,et al. Inter-society consensus for the management of peripheral arterial disease. , 2007, International angiology : a journal of the International Union of Angiology.
[23] D. Bloch,et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[24] Johannes Lammer,et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.
[25] Martin Schillinger,et al. Long-Segment SFA Stenting—The Dark Sides: In-Stent Restenosis, Clinical Deterioration, and Stent Fractures , 2005, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.
[26] Christopher Piorkowski,et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.
[27] A. Boulton,et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. , 2001, Diabetes care.
[28] A. Baumbach,et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.
[29] A. Küttner,et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. , 1997, Circulation.
[30] R. Kester,et al. Quality of life analysis in patients with lower limb ischaemia: suggestions for European standardisation. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[31] D. Scheinert,et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. , 2014, JACC. Cardiovascular interventions.
[32] John V. White,et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.